HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
30:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
practice.  symptoms generally occur  within four  to  six :@0.076190:0.084931:0.485130:0.084931:0.485130:0.069149:0.076190:0.069149:0.010311:0.004551:0.010326:0.009782:0.005125:0.003024:0.009782:0.009827:0.004188:0.004188:0.002903:0.007529:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.007091:0.010175:0.009827:0.009223:0.009827:0.004551:0.010326:0.003024:0.003024:0.008104:0.007091:0.009903:0.009782:0.009782:0.009192:0.004551:0.004188:0.002888:0.012564:0.003024:0.005125:0.009223:0.003024:0.009223:0.007091:0.004747:0.009903:0.009192:0.004551:0.004188:0.002888:0.005125:0.009903:0.004188:0.002888:0.005866:0.003024:0.007257:0.004188
weeks of starting therapy, but may occasionally occur :@0.076190:0.099190:0.485145:0.099190:0.485145:0.083407:0.076190:0.083407:0.012564:0.009827:0.009827:0.007590:0.005866:0.005231:0.009903:0.004747:0.005231:0.005866:0.005125:0.010326:0.004551:0.005125:0.003024:0.009223:0.010175:0.005231:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.005231:0.010311:0.009192:0.005125:0.005231:0.014182:0.010326:0.008104:0.005231:0.009903:0.009782:0.009782:0.010326:0.005866:0.003024:0.009903:0.009223:0.010326:0.003024:0.003024:0.008104:0.005246:0.009903:0.009782:0.009782:0.009192:0.004551:0.004188
after several years of treatment. Classically, symptoms :@0.076190:0.113449:0.485115:0.113449:0.485115:0.097666:0.076190:0.097666:0.010326:0.004747:0.005125:0.009827:0.004551:0.005851:0.005866:0.009827:0.008376:0.009827:0.004551:0.010326:0.003024:0.005866:0.008104:0.009827:0.010326:0.004551:0.005866:0.005866:0.009903:0.004747:0.005851:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009812:0.009223:0.005125:0.004188:0.005851:0.012292:0.003024:0.010326:0.005866:0.005866:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.004188:0.005881:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.004188
tend to be symmetrical and proximal, affecting mainly :@0.076190:0.127707:0.485115:0.127707:0.485115:0.111925:0.076190:0.111925:0.005125:0.009827:0.009223:0.010357:0.005065:0.005125:0.009903:0.005065:0.010311:0.009827:0.005080:0.005866:0.008104:0.014182:0.014182:0.009827:0.005125:0.004551:0.003024:0.009782:0.010326:0.003024:0.005080:0.010326:0.009223:0.010357:0.005080:0.010311:0.004551:0.009903:0.007257:0.003024:0.014182:0.010326:0.003024:0.004188:0.005080:0.010326:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.009223:0.010175:0.005065:0.014182:0.010326:0.003024:0.009223:0.003024:0.008104:0.004188
the muscles of the shoulder and hip girdles.:@0.076190:0.141966:0.391664:0.141966:0.391664:0.126183:0.076190:0.126183:0.005125:0.009223:0.009827:0.004188:0.014182:0.009192:0.005866:0.009782:0.003024:0.009827:0.005866:0.004188:0.009903:0.004747:0.004188:0.005125:0.009223:0.009827:0.004188:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.009827:0.004551:0.004188:0.010326:0.009223:0.010357:0.004188:0.009223:0.003024:0.010311:0.004188:0.010175:0.003024:0.004551:0.010357:0.003024:0.009827:0.005866:0.004188
10:@0.391638:0.136662:0.401354:0.136662:0.401354:0.127509:0.391638:0.127509:0.004858:0.004858
Although  there  is  no  universally  agreed  upon  defini:@0.090476:0.156219:0.476148:0.156219:0.476148:0.140436:0.090476:0.140436:0.011037:0.002873:0.004974:0.009071:0.009752:0.009041:0.010024:0.009071:0.004188:0.003009:0.004974:0.009071:0.009676:0.004400:0.009676:0.004188:0.003009:0.002873:0.005715:0.004188:0.003009:0.009071:0.009752:0.004188:0.003009:0.009041:0.009071:0.002873:0.008225:0.009676:0.004400:0.005715:0.010175:0.002873:0.002873:0.007953:0.004188:0.003009:0.010175:0.010024:0.004400:0.009676:0.009676:0.010205:0.004188:0.003009:0.009041:0.010160:0.009752:0.009071:0.004188:0.003009:0.010205:0.009676:0.003606:0.003606:0.009071:0.003024
-:@0.475996:0.156219:0.481016:0.156219:0.481016:0.140436:0.475996:0.140436:0.005020
tion for statin-associated muscle symptoms (sAMs), the :@0.076189:0.170477:0.485128:0.170477:0.485128:0.154695:0.076189:0.154695:0.004974:0.002873:0.009752:0.009071:0.006032:0.004596:0.009752:0.004400:0.006032:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.004868:0.010175:0.005715:0.005715:0.009752:0.009631:0.002873:0.010175:0.004974:0.009676:0.010205:0.006032:0.014030:0.009041:0.005715:0.009631:0.002873:0.009676:0.006032:0.005715:0.007953:0.014030:0.010160:0.004974:0.009752:0.014030:0.005715:0.006032:0.005428:0.007378:0.011037:0.013743:0.007378:0.005428:0.004037:0.006032:0.004974:0.009071:0.009827:0.004188
following terms are frequently used. Myalgia can cause :@0.076189:0.184736:0.485174:0.184736:0.485174:0.168953:0.076189:0.168953:0.004596:0.009752:0.002873:0.002873:0.009752:0.012413:0.002873:0.009071:0.010024:0.005050:0.004974:0.009676:0.004400:0.014030:0.005715:0.005050:0.010175:0.004400:0.009676:0.005050:0.004596:0.004400:0.009676:0.010160:0.009041:0.009676:0.009071:0.004974:0.002873:0.007953:0.005050:0.009041:0.005715:0.009676:0.010205:0.004037:0.005050:0.013743:0.007953:0.010175:0.002873:0.010024:0.002873:0.010175:0.005050:0.009631:0.010175:0.009071:0.005050:0.009631:0.010175:0.009041:0.005715:0.009827:0.004188
unexplained muscle discomfort often described as \flu-:@0.076189:0.198994:0.480925:0.198994:0.480925:0.183212:0.076189:0.183212:0.009041:0.009071:0.009676:0.007106:0.010160:0.002873:0.010175:0.002873:0.009071:0.009676:0.010205:0.005942:0.014030:0.009041:0.005715:0.009631:0.002873:0.009676:0.005942:0.010205:0.002873:0.005715:0.009631:0.009752:0.014030:0.004596:0.009752:0.004400:0.004974:0.005942:0.009752:0.004596:0.004974:0.009676:0.009071:0.005942:0.010205:0.009676:0.005715:0.009631:0.004400:0.002873:0.010160:0.009676:0.010205:0.005942:0.010175:0.005715:0.005942:0.004521:0.003591:0.003591:0.009041:0.005020
like\ symptoms with normal creatine kinase (CK) levels. :@0.076189:0.213253:0.485128:0.213253:0.485128:0.197470:0.076189:0.197470:0.002873:0.002873:0.007439:0.009676:0.004521:0.006426:0.005715:0.007953:0.014030:0.010160:0.004974:0.009752:0.014030:0.005715:0.006426:0.012413:0.002873:0.004974:0.009071:0.006426:0.009071:0.009752:0.004400:0.014030:0.010175:0.002873:0.006426:0.009631:0.004400:0.009676:0.010175:0.004974:0.002873:0.009071:0.009676:0.006426:0.007439:0.002873:0.009071:0.010175:0.005715:0.009676:0.006426:0.005428:0.012141:0.008784:0.005428:0.006426:0.002873:0.009676:0.008225:0.009676:0.002873:0.005715:0.004188:0.004188
Complaints  may  include  muscle  aches,  soreness,  stiff-:@0.076189:0.227512:0.480910:0.227512:0.480910:0.211729:0.076189:0.211729:0.012141:0.009752:0.014030:0.010160:0.002873:0.010175:0.002873:0.009071:0.004974:0.005715:0.004188:0.003583:0.014030:0.010175:0.007953:0.004188:0.003583:0.002873:0.009071:0.009631:0.002873:0.009041:0.010205:0.009676:0.004188:0.003583:0.014030:0.009041:0.005715:0.009631:0.002873:0.009676:0.004188:0.003583:0.010175:0.009631:0.009071:0.009676:0.005715:0.004037:0.004188:0.003583:0.005715:0.009752:0.004400:0.009676:0.009071:0.009676:0.005715:0.005715:0.004037:0.004188:0.003583:0.005715:0.004974:0.002873:0.004596:0.004596:0.005020
ness, tenderness, and cramps with or shortly after exer-:@0.076189:0.241770:0.480971:0.241770:0.480971:0.225988:0.076189:0.225988:0.009071:0.009676:0.005715:0.005715:0.004037:0.005851:0.004974:0.009676:0.009071:0.010205:0.009676:0.004400:0.009071:0.009676:0.005715:0.005715:0.004037:0.005866:0.010175:0.009071:0.010205:0.005866:0.009631:0.004400:0.010175:0.014030:0.010160:0.005715:0.005851:0.012413:0.002873:0.004974:0.009071:0.005866:0.009752:0.004400:0.005866:0.005715:0.009071:0.009752:0.004400:0.004974:0.002873:0.007953:0.005851:0.010175:0.004596:0.004974:0.009676:0.004400:0.005851:0.009676:0.007106:0.009676:0.004400:0.005020
cise (not nocturnal cramping).  similar symptoms may :@0.076189:0.256029:0.485174:0.256029:0.485174:0.240246:0.076189:0.240246:0.009631:0.002873:0.005715:0.009676:0.008270:0.005428:0.009071:0.009752:0.004974:0.008270:0.009071:0.009752:0.009631:0.004974:0.009041:0.004400:0.009071:0.010175:0.002873:0.008270:0.009631:0.004400:0.010175:0.014030:0.010160:0.002873:0.009071:0.010024:0.005428:0.004037:0.004188:0.004082:0.007378:0.002873:0.014030:0.002873:0.002873:0.010175:0.004400:0.008270:0.005715:0.007953:0.014030:0.010160:0.004974:0.009752:0.014030:0.005715:0.008270:0.014030:0.010175:0.008104:0.004188
occur in patients with minor elevations in CK (approxi-:@0.076189:0.270288:0.480986:0.270288:0.480986:0.254505:0.076189:0.254505:0.009752:0.009631:0.009631:0.009041:0.004400:0.006547:0.002873:0.009071:0.006547:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.006547:0.012413:0.002873:0.004974:0.009071:0.006547:0.014030:0.002873:0.009071:0.009752:0.004400:0.006547:0.009676:0.002873:0.009676:0.008225:0.010175:0.004974:0.002873:0.009752:0.009071:0.005715:0.006547:0.002873:0.009071:0.006547:0.012141:0.008784:0.006547:0.005428:0.010175:0.010160:0.010160:0.004400:0.009752:0.007106:0.002873:0.005020
mately four to 10 times the upper limit of normal [ULN]). :@0.076189:0.284546:0.485128:0.284546:0.485128:0.268764:0.076189:0.268764:0.014030:0.010175:0.004974:0.009676:0.002873:0.007953:0.005186:0.004596:0.009752:0.009041:0.004400:0.005186:0.004974:0.009752:0.005186:0.008225:0.008225:0.005186:0.004974:0.002873:0.014030:0.009676:0.005715:0.005186:0.004974:0.009071:0.009676:0.005186:0.009041:0.010160:0.010160:0.009676:0.004400:0.005186:0.002873:0.002873:0.014030:0.002873:0.004974:0.005186:0.009752:0.004596:0.005186:0.009071:0.009752:0.004400:0.014030:0.010175:0.002873:0.005186:0.005156:0.009752:0.006834:0.011037:0.005156:0.005428:0.004188:0.004188
Regulators frequently use the term \myopathy\ in patients :@0.076189:0.298805:0.485158:0.298805:0.485158:0.283022:0.076189:0.283022:0.009026:0.009676:0.010024:0.009041:0.002873:0.010175:0.004974:0.009752:0.004400:0.005715:0.003235:0.004596:0.004400:0.009676:0.010160:0.009041:0.009676:0.009071:0.004974:0.002873:0.007953:0.003235:0.009041:0.005715:0.009676:0.003235:0.004974:0.009071:0.009676:0.003235:0.004974:0.009676:0.004400:0.014030:0.003235:0.004521:0.014030:0.007953:0.009752:0.010160:0.010175:0.004974:0.009071:0.007953:0.004521:0.003235:0.002873:0.009071:0.003235:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005866:0.004188
with muscle symptoms and CK levels more than 10 times :@0.076189:0.313063:0.485128:0.313063:0.485128:0.297281:0.076189:0.297281:0.012413:0.002873:0.004974:0.009071:0.004188:0.014030:0.009041:0.005715:0.009631:0.002873:0.009676:0.004188:0.005715:0.007953:0.014030:0.010160:0.004974:0.009752:0.014030:0.005715:0.004188:0.010175:0.009071:0.010205:0.004188:0.012141:0.008784:0.004188:0.002873:0.009676:0.008225:0.009676:0.002873:0.005715:0.004188:0.014030:0.009752:0.004400:0.009676:0.004188:0.004974:0.009071:0.010175:0.009071:0.004188:0.008225:0.008225:0.004188:0.004974:0.002873:0.014030:0.009676:0.005866:0.004188
the ULN. patients with very marked elevations in CK (usu-:@0.076189:0.327322:0.481016:0.327322:0.481016:0.311539:0.076189:0.311539:0.004974:0.009071:0.009676:0.004173:0.009752:0.006834:0.011037:0.004037:0.004173:0.008799:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.004173:0.012413:0.002873:0.004974:0.009071:0.004173:0.008225:0.009676:0.004400:0.007953:0.004173:0.014030:0.010175:0.004400:0.007439:0.009676:0.010205:0.004173:0.009676:0.002873:0.009676:0.008225:0.010175:0.004974:0.002873:0.009752:0.009071:0.005715:0.004173:0.002873:0.009071:0.004173:0.012141:0.008784:0.004173:0.005428:0.009041:0.005715:0.009041:0.005020
ally more than 40 times the ULN) and evidence of renal :@0.076189:0.341581:0.485113:0.341581:0.485113:0.325798:0.076189:0.325798:0.010175:0.002873:0.002873:0.007953:0.005004:0.014030:0.009752:0.004400:0.009676:0.005004:0.004974:0.009071:0.010175:0.009071:0.005004:0.008225:0.008225:0.005004:0.004974:0.002873:0.014030:0.009676:0.005715:0.005004:0.004974:0.009071:0.009676:0.005004:0.009752:0.006834:0.011037:0.005428:0.005004:0.010175:0.009071:0.010205:0.005004:0.009676:0.008225:0.002873:0.010205:0.009676:0.009071:0.009631:0.009676:0.005004:0.009752:0.004596:0.005004:0.004400:0.009676:0.009071:0.010175:0.003024:0.004188
impairment  or  myoglobinuria  have  rhabdomyolysis  –  a :@0.076189:0.355839:0.485098:0.355839:0.485098:0.340057:0.076189:0.340057:0.002873:0.014030:0.010160:0.010175:0.002873:0.004400:0.014030:0.009676:0.009071:0.004974:0.004188:0.002449:0.009752:0.004400:0.004188:0.002449:0.014030:0.007953:0.009752:0.010024:0.002873:0.009752:0.010160:0.002873:0.009071:0.009041:0.004400:0.002873:0.010175:0.004188:0.002449:0.009071:0.010175:0.008225:0.009676:0.004188:0.002449:0.004400:0.009071:0.010175:0.010160:0.010205:0.009752:0.014030:0.007953:0.009752:0.002873:0.007953:0.005715:0.002873:0.005715:0.004188:0.002449:0.007408:0.004188:0.002449:0.010326:0.004188
serious disorder that requires rapid medical intervention. :@0.076189:0.370098:0.485128:0.370098:0.485128:0.354315:0.076189:0.354315:0.005715:0.009676:0.004400:0.002873:0.009752:0.009041:0.005715:0.004853:0.010205:0.002873:0.005715:0.009752:0.004400:0.010205:0.009676:0.004400:0.004853:0.004974:0.009071:0.010175:0.004974:0.004853:0.004400:0.009676:0.010160:0.009041:0.002873:0.004400:0.009676:0.005715:0.004853:0.004400:0.010175:0.010160:0.002873:0.010205:0.004853:0.014030:0.009676:0.010205:0.002873:0.009631:0.010175:0.002873:0.004853:0.002873:0.009071:0.004974:0.009676:0.004400:0.008225:0.009676:0.009071:0.004974:0.002873:0.009752:0.009071:0.004188:0.004188
Occasionally, patients have elevated CK levels in the :@0.076189:0.384357:0.485158:0.384357:0.485158:0.368574:0.076189:0.368574:0.012987:0.009631:0.009631:0.010175:0.005715:0.002873:0.009752:0.009071:0.010175:0.002873:0.002873:0.007953:0.004037:0.007287:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.007287:0.009071:0.010175:0.008225:0.009676:0.007287:0.009676:0.002873:0.009676:0.008225:0.010175:0.004974:0.009676:0.010205:0.007287:0.012141:0.008784:0.007287:0.002873:0.009676:0.008225:0.009676:0.002873:0.005715:0.007287:0.002873:0.009071:0.007287:0.004974:0.009071:0.009827:0.004188
absence of any muscle symptoms. This should no longer :@0.076189:0.398615:0.485143:0.398615:0.485143:0.382833:0.076189:0.382833:0.010175:0.010160:0.005715:0.009676:0.009071:0.009631:0.009676:0.004551:0.009752:0.004596:0.004551:0.010175:0.009071:0.007953:0.004551:0.014030:0.009041:0.005715:0.009631:0.002873:0.009676:0.004551:0.005715:0.007953:0.014030:0.010160:0.004974:0.009752:0.014030:0.005715:0.004037:0.004551:0.006290:0.009071:0.002873:0.005715:0.004551:0.005715:0.009071:0.009752:0.009041:0.002873:0.010205:0.004551:0.009071:0.009752:0.004551:0.002873:0.009752:0.009071:0.010024:0.009676:0.004551:0.004188
be a frequent finding as guidelines advise against routine :@0.076189:0.412874:0.485143:0.412874:0.485143:0.397091:0.076189:0.397091:0.010160:0.009676:0.003372:0.010175:0.003372:0.004596:0.004400:0.009676:0.010160:0.009041:0.009676:0.009071:0.004974:0.003372:0.003606:0.003606:0.009071:0.010205:0.002873:0.009071:0.010024:0.003372:0.010175:0.005715:0.003372:0.010024:0.009041:0.002873:0.010205:0.009676:0.002873:0.002873:0.009071:0.009676:0.005715:0.003372:0.010175:0.010205:0.008225:0.002873:0.005715:0.009676:0.003372:0.010175:0.010024:0.010175:0.002873:0.009071:0.005715:0.004974:0.003372:0.004400:0.009752:0.009041:0.004974:0.002873:0.009071:0.009827:0.004188
monitoring of CK in asymptomatic patients. Exercise and :@0.076189:0.427132:0.485189:0.427132:0.485189:0.411350:0.076189:0.411350:0.014030:0.009752:0.009071:0.002873:0.004974:0.009752:0.004400:0.002873:0.009071:0.010024:0.004007:0.009752:0.004596:0.004007:0.012141:0.008784:0.004007:0.002873:0.009071:0.004007:0.010175:0.005715:0.007953:0.014030:0.010160:0.004974:0.009752:0.014030:0.010175:0.004974:0.002873:0.009631:0.004007:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.005715:0.004037:0.004007:0.007953:0.007106:0.009676:0.004400:0.009631:0.002873:0.005715:0.009676:0.004007:0.010175:0.009071:0.010357:0.004188
thyroid disorders are common explanations for inciden-:@0.076189:0.441391:0.480955:0.441391:0.480955:0.425608:0.076189:0.425608:0.004974:0.009071:0.007953:0.004400:0.009752:0.002873:0.010205:0.005549:0.010205:0.002873:0.005715:0.009752:0.004400:0.010205:0.009676:0.004400:0.005715:0.005549:0.010175:0.004400:0.009676:0.005549:0.009631:0.009752:0.014030:0.014030:0.009752:0.009071:0.005549:0.009676:0.007106:0.010160:0.002873:0.010175:0.009071:0.010175:0.004974:0.002873:0.009752:0.009071:0.005715:0.005549:0.004596:0.009752:0.004400:0.005549:0.002873:0.009071:0.009631:0.002873:0.010205:0.009676:0.009071:0.005020
tally discovered elevated CK levels.:@0.076189:0.455650:0.331171:0.455650:0.331171:0.439867:0.076189:0.439867:0.004974:0.010175:0.002873:0.002873:0.007953:0.004037:0.010205:0.002873:0.005715:0.009631:0.009752:0.008225:0.009676:0.004400:0.009676:0.010205:0.004037:0.009676:0.002873:0.009676:0.008225:0.010175:0.004974:0.009676:0.010205:0.004037:0.012141:0.008784:0.004037:0.002873:0.009676:0.008225:0.009676:0.002873:0.005715:0.004188
The risk of statin-associated muscle adverse events in-:@0.090476:0.469908:0.480940:0.469908:0.480940:0.454126:0.090476:0.454126:0.006441:0.009223:0.009827:0.004082:0.004551:0.003024:0.005866:0.007590:0.004097:0.009903:0.004747:0.004097:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005020:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.004097:0.014182:0.009192:0.005866:0.009782:0.003024:0.009827:0.004097:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.004097:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004097:0.003024:0.009223:0.005020
creases if statins are used with enzyme inhibitors. simva-:@0.076189:0.484167:0.480955:0.484167:0.480955:0.468384:0.076189:0.468384:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005866:0.004127:0.003024:0.004747:0.004127:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004127:0.010326:0.004551:0.009827:0.004127:0.009192:0.005866:0.009827:0.010357:0.004127:0.012564:0.003024:0.005125:0.009223:0.004127:0.009827:0.009223:0.006426:0.008104:0.014182:0.009827:0.004112:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.004127:0.007529:0.003024:0.014182:0.008376:0.010326:0.005020
statin, and to a lesser extent atorvastatin, are meta-:@0.076189:0.498426:0.480925:0.498426:0.480925:0.482643:0.076189:0.482643:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.007575:0.010326:0.009223:0.010357:0.007575:0.005125:0.009903:0.007575:0.010326:0.007575:0.003024:0.009827:0.005866:0.005866:0.009827:0.004551:0.007575:0.009827:0.007257:0.005125:0.009827:0.009207:0.005125:0.007575:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.007575:0.010326:0.004551:0.009827:0.007575:0.014182:0.009827:0.005125:0.010326:0.005020
bolised by the hepatic isoenzyme CYp3A4.  CYp3A4 :@0.076189:0.512684:0.485143:0.512684:0.485143:0.496902:0.076189:0.496902:0.010311:0.009903:0.003024:0.003024:0.005866:0.009827:0.010357:0.009238:0.010311:0.008104:0.009238:0.005125:0.009223:0.009827:0.009238:0.009223:0.009827:0.010311:0.010326:0.005125:0.003024:0.009782:0.009238:0.003024:0.005866:0.009903:0.009827:0.009223:0.006426:0.008104:0.014182:0.009827:0.009238:0.012292:0.008950:0.008950:0.008376:0.011188:0.008376:0.004188:0.004188:0.005035:0.012292:0.008950:0.008950:0.008376:0.011188:0.008376:0.004188
Inhibitors may increase the plasma  concentration  of :@0.076189:0.526943:0.485128:0.526943:0.485128:0.511160:0.076189:0.511160:0.003417:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.008028:0.014182:0.010326:0.008104:0.008028:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.008028:0.005125:0.009223:0.009827:0.008028:0.010311:0.003024:0.010326:0.005866:0.014182:0.010326:0.004188:0.003855:0.009782:0.009903:0.009223:0.009782:0.009827:0.009223:0.005125:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.003825:0.009903:0.004747:0.004188
these  statins, increasing the  risk of  adverse reactions. :@0.076189:0.541201:0.485143:0.541201:0.485143:0.525419:0.076189:0.525419:0.005125:0.009223:0.009827:0.005866:0.009827:0.004188:0.002994:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004188:0.007197:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.003024:0.009223:0.010175:0.007197:0.005125:0.009223:0.009827:0.004188:0.002994:0.004551:0.003024:0.005866:0.007590:0.007197:0.009903:0.004747:0.004188:0.002994:0.010326:0.010357:0.008376:0.009827:0.004551:0.005866:0.009827:0.007197:0.004551:0.009827:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188
If  a potent  CYp3A4  inhibitor,  such  as erythromycin,  is :@0.076189:0.555460:0.485128:0.555460:0.485128:0.539677:0.076189:0.539677:0.003417:0.004747:0.004188:0.003069:0.010326:0.007272:0.010311:0.009903:0.005125:0.009827:0.009223:0.005125:0.004188:0.003069:0.012292:0.008950:0.008950:0.008376:0.011188:0.008376:0.004188:0.003069:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.004188:0.004188:0.003069:0.005866:0.009192:0.009782:0.009223:0.004188:0.003069:0.010326:0.005866:0.007272:0.009827:0.004551:0.008104:0.005125:0.009223:0.004551:0.009903:0.014182:0.008104:0.009782:0.003024:0.009223:0.004188:0.004188:0.003069:0.003024:0.005866:0.004188
called for,  then simvastatin or  atorvastatin should be :@0.076189:0.569719:0.485143:0.569719:0.485143:0.553936:0.076189:0.553936:0.009782:0.010326:0.003024:0.003024:0.009827:0.010357:0.007393:0.004747:0.009903:0.004551:0.004188:0.004188:0.003190:0.005125:0.009223:0.009827:0.009223:0.007393:0.005866:0.003024:0.014182:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.007393:0.009903:0.004551:0.004188:0.003190:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.007393:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.007393:0.010311:0.009827:0.004188
stopped for the duration of therapy. Fluvastatin, pravas-:@0.076189:0.583977:0.480955:0.583977:0.480955:0.568195:0.076189:0.568195:0.005866:0.005125:0.009903:0.010311:0.010311:0.009827:0.010357:0.003689:0.004747:0.009903:0.004551:0.003674:0.005125:0.009223:0.009827:0.003674:0.010357:0.009192:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.003674:0.009903:0.004747:0.003674:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.003689:0.007333:0.003024:0.009192:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.003689:0.010311:0.004551:0.010326:0.008376:0.010326:0.005881:0.005020
tatin and rosuvastatin are not significantly metabolised :@0.076189:0.598236:0.485098:0.598236:0.485098:0.582453:0.076189:0.582453:0.005125:0.010326:0.005125:0.003024:0.009223:0.005020:0.010326:0.009223:0.010357:0.005020:0.004551:0.009903:0.005866:0.009192:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005020:0.010326:0.004551:0.009827:0.005020:0.009223:0.009903:0.005110:0.005020:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003024:0.008104:0.005020:0.014182:0.009827:0.005125:0.010326:0.010311:0.009903:0.003024:0.003024:0.005866:0.009827:0.010357:0.004188
by CYp3A4 and are less susceptible to CYp interactions. :@0.076189:0.612495:0.485143:0.612495:0.485143:0.596712:0.076189:0.596712:0.010311:0.008104:0.004067:0.012292:0.008950:0.008950:0.008376:0.011188:0.008376:0.004052:0.010326:0.009223:0.010357:0.004052:0.010326:0.004551:0.009827:0.004052:0.003024:0.009827:0.005866:0.005866:0.004067:0.005866:0.009192:0.005866:0.009782:0.009827:0.010311:0.005125:0.003024:0.010311:0.003024:0.009827:0.004067:0.005125:0.009903:0.004052:0.012292:0.008950:0.008950:0.004052:0.003024:0.009223:0.005125:0.009827:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188
simvastatin  is  now contra-indicated with cyclosporin, :@0.076189:0.626753:0.485128:0.626753:0.485128:0.610971:0.076189:0.610971:0.007529:0.003024:0.014182:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.003719:0.003024:0.005866:0.004188:0.003719:0.009223:0.009903:0.012564:0.007892:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010341:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.007892:0.012564:0.003024:0.005125:0.009223:0.007892:0.009782:0.008104:0.009782:0.003024:0.009903:0.005866:0.010311:0.009903:0.004551:0.003024:0.009223:0.004188:0.004188
danazol and gemfibrozil. The maximum recommended :@0.076189:0.641012:0.485143:0.641012:0.485143:0.625229:0.076189:0.625229:0.010357:0.010326:0.009223:0.010326:0.006426:0.009903:0.003024:0.004490:0.010326:0.009223:0.010357:0.004490:0.010175:0.009827:0.014182:0.003681:0.003681:0.010311:0.004551:0.009903:0.006426:0.003024:0.003024:0.004188:0.004490:0.006441:0.009223:0.009827:0.004490:0.014182:0.010326:0.007257:0.003024:0.014182:0.009192:0.014182:0.004490:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188
dose  of  simvastatin  in conjunction  with amlodipine or :@0.076189:0.655270:0.485128:0.655270:0.485128:0.639488:0.076189:0.639488:0.010357:0.009903:0.005866:0.009827:0.004188:0.002434:0.009903:0.004747:0.004188:0.002434:0.005866:0.003024:0.014182:0.008376:0.010326:0.005881:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.002434:0.003024:0.009223:0.006637:0.009782:0.009903:0.009223:0.003069:0.009192:0.009207:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.002434:0.012564:0.003024:0.005125:0.009223:0.006637:0.010326:0.014182:0.003024:0.009903:0.010357:0.003024:0.010311:0.003024:0.009223:0.009827:0.006637:0.009903:0.004551:0.004188
diltiazem is 20 mg/day.  :@0.076189:0.669529:0.257566:0.669486:0.257566:0.653704:0.076189:0.653746:0.010357:0.003024:0.003024:0.005125:0.003024:0.010326:0.006426:0.009827:0.014182:0.004188:0.003024:0.005866:0.004188:0.008376:0.008376:0.004188:0.014182:0.010175:0.006607:0.010357:0.010326:0.008104:0.004188:0.009731:0.200105
11:@0.243659:0.664188:0.253375:0.664188:0.253375:0.655034:0.243659:0.655034:0.004858:0.004858
There is no doubt that many patients experience mus-:@0.090471:0.683745:0.480935:0.683745:0.480935:0.667962:0.090471:0.667962:0.006441:0.009223:0.009827:0.004551:0.009827:0.003674:0.003024:0.005866:0.003704:0.009223:0.009903:0.003689:0.010357:0.009903:0.009192:0.010311:0.005125:0.003689:0.005125:0.009223:0.010326:0.005125:0.003689:0.014182:0.010326:0.009223:0.008104:0.003689:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003689:0.009827:0.007257:0.010311:0.009827:0.004551:0.003024:0.009827:0.009223:0.009782:0.009827:0.003689:0.014182:0.009192:0.005866:0.005020
cle symptoms while  taking a statin. However, it is  not :@0.076183:0.698004:0.485123:0.698004:0.485123:0.682221:0.076183:0.682221:0.009782:0.003024:0.009827:0.006819:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.006819:0.012564:0.009223:0.003024:0.003024:0.009827:0.004188:0.002646:0.005125:0.010326:0.007590:0.003024:0.009223:0.010175:0.006819:0.010326:0.006819:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.006819:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.006819:0.003024:0.005125:0.006819:0.003024:0.005866:0.004188:0.002646:0.009223:0.009903:0.005125:0.004188
always clear that these symptoms are causally related :@0.076183:0.712262:0.485123:0.712262:0.485123:0.696480:0.076183:0.696480:0.010326:0.003024:0.012564:0.010326:0.008104:0.005866:0.005216:0.009782:0.003024:0.009827:0.010326:0.004551:0.005201:0.005125:0.009223:0.010326:0.005125:0.005201:0.005125:0.009223:0.009827:0.005866:0.009827:0.005201:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.005201:0.010326:0.004551:0.009827:0.005201:0.009782:0.010326:0.009192:0.005866:0.010326:0.003024:0.003024:0.008104:0.005216:0.004551:0.009827:0.003024:0.010326:0.005125:0.009827:0.010357:0.004188
to statins. For instance, muscle symptoms are reported :@0.076183:0.726521:0.485123:0.726521:0.485123:0.710738:0.076183:0.710738:0.005125:0.009903:0.005428:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004188:0.005443:0.007333:0.009903:0.004551:0.005428:0.003024:0.009223:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.005428:0.014182:0.009192:0.005866:0.009782:0.003024:0.009827:0.005443:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.005443:0.010326:0.004551:0.009827:0.005428:0.004551:0.009827:0.010311:0.009903:0.004551:0.005125:0.009827:0.010357:0.004188
very commonly in observational studies, but in double-:@0.076183:0.740780:0.480935:0.740780:0.480935:0.724997:0.076183:0.724997:0.008376:0.009827:0.004551:0.008104:0.005080:0.009782:0.009903:0.014182:0.014182:0.009903:0.009223:0.003024:0.008104:0.005080:0.003024:0.009223:0.005080:0.009903:0.010311:0.005866:0.009827:0.004551:0.008376:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.005095:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.005095:0.010311:0.009192:0.005125:0.005080:0.003024:0.009223:0.005095:0.010357:0.009903:0.009192:0.010311:0.003024:0.009827:0.005020
blind, placebo-controlled  studies, the  rates  of  muscle :@0.076183:0.755038:0.485138:0.755038:0.485138:0.739256:0.076183:0.739256:0.010311:0.003024:0.003024:0.009223:0.010357:0.004188:0.006940:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.005020:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.003024:0.009827:0.010357:0.004188:0.002737:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.006940:0.005125:0.009223:0.009827:0.004188:0.002737:0.004551:0.010326:0.005125:0.009827:0.005866:0.004188:0.002737:0.009903:0.004747:0.004188:0.002737:0.014182:0.009192:0.005866:0.009782:0.003024:0.009827:0.004188
symptoms were very similar in the statin and placebo :@0.076183:0.769297:0.485108:0.769297:0.485108:0.753514:0.076183:0.753514:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.006395:0.012564:0.009827:0.004551:0.009827:0.006380:0.008376:0.009827:0.004551:0.008104:0.006380:0.005866:0.003024:0.014182:0.003024:0.003024:0.010326:0.004551:0.006395:0.003024:0.009223:0.006380:0.005125:0.009223:0.009827:0.006380:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.006380:0.010326:0.009223:0.010357:0.006380:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188
group. When pCsK9 inhibitors were studied as an alter-:@0.076183:0.783555:0.480935:0.783555:0.480935:0.767773:0.076183:0.767773:0.010175:0.004551:0.009903:0.009192:0.010311:0.004188:0.005020:0.014514:0.009223:0.009827:0.009223:0.005020:0.008950:0.012292:0.007529:0.008935:0.008376:0.005020:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005020:0.012564:0.009827:0.004551:0.009827:0.005020:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.010357:0.005020:0.010326:0.005866:0.005020:0.010326:0.009223:0.005020:0.010326:0.003024:0.005125:0.009827:0.004551:0.005020
native therapy for patients with statin intolerance, many :@0.076183:0.797814:0.485108:0.797814:0.485108:0.782031:0.076183:0.782031:0.009223:0.010326:0.005125:0.003024:0.008376:0.009827:0.003553:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.003553:0.004747:0.009903:0.004551:0.003553:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003553:0.012564:0.003024:0.005125:0.009223:0.003553:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.003553:0.003024:0.009223:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.009223:0.009782:0.009827:0.004188:0.003538:0.014182:0.010326:0.009223:0.008104:0.004188
patients with  a  history  of  not  tolerating  a  minimum of :@0.076183:0.812073:0.485108:0.812073:0.485108:0.796290:0.076183:0.796290:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006531:0.012564:0.003024:0.005125:0.009223:0.004188:0.002328:0.010326:0.004188:0.002328:0.009223:0.003024:0.005866:0.005125:0.009903:0.004551:0.008104:0.004188:0.002328:0.009903:0.004747:0.004188:0.002328:0.009223:0.009903:0.005110:0.004188:0.002328:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.003024:0.009223:0.010175:0.004188:0.002328:0.010326:0.004188:0.002328:0.014182:0.003024:0.009223:0.003024:0.014182:0.009192:0.014182:0.006531:0.009903:0.004747:0.004188
two statins were either able to tolerate a statin during :@0.076183:0.826331:0.485138:0.826331:0.485138:0.810549:0.076183:0.810549:0.005125:0.012564:0.009903:0.005836:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.005836:0.012564:0.009827:0.004551:0.009827:0.005836:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.005836:0.010326:0.010311:0.003024:0.009827:0.005836:0.005125:0.009903:0.005836:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.005821:0.010326:0.005836:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005836:0.010357:0.009192:0.004551:0.003024:0.009223:0.010175:0.004188
the double-blind crossover statin challenge or reported :@0.076183:0.840590:0.485138:0.840590:0.485138:0.824807:0.076183:0.824807:0.005125:0.009223:0.009827:0.004385:0.010357:0.009903:0.009192:0.010311:0.003024:0.009827:0.005020:0.010311:0.003024:0.003024:0.009238:0.010357:0.004400:0.009782:0.004551:0.009903:0.005866:0.005866:0.009903:0.008376:0.009827:0.004551:0.004385:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004400:0.009782:0.009223:0.010326:0.003024:0.003024:0.009827:0.009223:0.010175:0.009827:0.004400:0.009903:0.004551:0.004385:0.004551:0.009827:0.010311:0.009903:0.004551:0.005125:0.009827:0.010357:0.004188
muscle symptoms while on placebo.:@0.076183:0.854849:0.342808:0.854849:0.342808:0.839066:0.076183:0.839066:0.014182:0.009192:0.005866:0.009782:0.003024:0.009827:0.004188:0.005866:0.008104:0.014182:0.010311:0.005125:0.009903:0.014182:0.005866:0.004188:0.012564:0.009223:0.003024:0.003024:0.009827:0.004188:0.009903:0.009223:0.004188:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188
10:@0.342811:0.849534:0.352527:0.849534:0.352527:0.840381:0.342811:0.840381:0.004858:0.004858
Diabetes :@0.076190:0.886161:0.152793:0.886161:0.152793:0.867830:0.076190:0.867830:0.011759:0.004032:0.011087:0.011087:0.010751:0.005040:0.010751:0.007392:0.004704
Statin therapy is associated with a small, but definite, in:@0.076190:0.902590:0.475923:0.902590:0.475923:0.886808:0.076190:0.886808:0.007529:0.005125:0.010326:0.005125:0.003024:0.009223:0.003991:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.003991:0.003024:0.005866:0.003991:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.003991:0.012564:0.003024:0.005125:0.009223:0.003991:0.010326:0.003991:0.005866:0.014182:0.010326:0.003024:0.003024:0.004188:0.004007:0.010311:0.009192:0.005125:0.003991:0.010357:0.009827:0.003681:0.003681:0.009223:0.003024:0.005125:0.009827:0.004188:0.003991:0.003024:0.009223
-:@0.475923:0.902590:0.480942:0.902590:0.480942:0.886808:0.475923:0.886808:0.005020
crease in the risk of new-onset diabetes (NOD), and the :@0.076190:0.916849:0.485100:0.916849:0.485100:0.901066:0.076190:0.901066:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004022:0.003024:0.009223:0.004022:0.005125:0.009223:0.009827:0.004022:0.004551:0.003024:0.005866:0.007590:0.004022:0.009903:0.004747:0.004022:0.009223:0.009827:0.012564:0.005020:0.009903:0.009223:0.005866:0.009827:0.005110:0.004022:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004037:0.005579:0.011188:0.013138:0.011249:0.005579:0.004188:0.004022:0.010326:0.009223:0.010357:0.004022:0.005125:0.009223:0.009827:0.004188
risk of intensive statin therapy is slightly higher than that :@0.076190:0.931108:0.485145:0.931108:0.485145:0.915325:0.076190:0.915325:0.004551:0.003024:0.005866:0.007590:0.004808:0.009903:0.004747:0.004808:0.003024:0.009223:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.004808:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004808:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004808:0.003024:0.005866:0.004808:0.005866:0.003024:0.003024:0.010175:0.009223:0.005125:0.003024:0.008104:0.004808:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004793:0.005125:0.009223:0.010326:0.009223:0.004793:0.005125:0.009223:0.010326:0.005125:0.004188
of moderate statin therapy. Using modelling, one can :@0.076190:0.945366:0.485130:0.945366:0.485130:0.929584:0.076190:0.929584:0.009903:0.004747:0.006032:0.014182:0.009903:0.010357:0.009827:0.004551:0.010326:0.005125:0.009827:0.006032:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.006048:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.006032:0.009903:0.005866:0.003024:0.009223:0.010175:0.006048:0.014182:0.009903:0.010357:0.009827:0.003024:0.003024:0.003024:0.009223:0.010175:0.004188:0.006032:0.009903:0.009223:0.009827:0.006032:0.009782:0.010326:0.009223:0.004188
estimate that high-dose statin therapy (e.g. atorvastatin :@0.519042:0.084930:0.927982:0.084930:0.927982:0.069148:0.519042:0.069148:0.009827:0.005866:0.005125:0.003024:0.014182:0.010326:0.005125:0.009827:0.003613:0.005125:0.009223:0.010326:0.005125:0.003598:0.009223:0.003024:0.010175:0.009223:0.005020:0.010357:0.009903:0.005866:0.009827:0.003598:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.003613:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.003598:0.005579:0.009827:0.004188:0.010175:0.004188:0.003598:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188
40 mg daily) may cause an excess of approximately 50 :@0.519042:0.099524:0.927982:0.099524:0.927982:0.083741:0.519042:0.083741:0.008376:0.008376:0.004445:0.014182:0.010175:0.004430:0.010357:0.010326:0.003024:0.003024:0.008104:0.005579:0.004445:0.014182:0.010326:0.008104:0.004445:0.009782:0.010326:0.009192:0.005866:0.009827:0.004445:0.010326:0.009223:0.004445:0.009827:0.007257:0.009782:0.009827:0.005866:0.005866:0.004445:0.009903:0.004747:0.004430:0.010326:0.010311:0.010311:0.004551:0.009903:0.007257:0.003024:0.014182:0.010326:0.005125:0.009827:0.003024:0.008104:0.004445:0.008376:0.008376:0.004188
to 100 cases of NOD in 10 000 treated individuals.  How-:@0.519042:0.114117:0.923802:0.114121:0.923802:0.098338:0.519042:0.098335:0.005125:0.009903:0.003583:0.008376:0.008376:0.008376:0.003598:0.009782:0.010326:0.005866:0.009827:0.005866:0.003598:0.009903:0.004747:0.003583:0.011188:0.013138:0.011249:0.003583:0.003024:0.009223:0.003598:0.008376:0.008376:0.003598:0.008376:0.008376:0.008376:0.003598:0.005125:0.004551:0.009827:0.010326:0.005125:0.009827:0.010357:0.003583:0.003024:0.009223:0.010357:0.003024:0.008376:0.003024:0.010357:0.009192:0.010326:0.003024:0.005866:0.004188:0.009745:0.003583:0.010326:0.009903:0.012564:0.261965
12:@0.872686:0.108822:0.882403:0.108822:0.882403:0.099668:0.872686:0.099668:0.004858:0.004858
ever, the net benefit remains positive, both in patients at :@0.519050:0.128714:0.927975:0.128714:0.927975:0.112931:0.519050:0.112931:0.009827:0.008376:0.009827:0.004551:0.004188:0.003356:0.005125:0.009223:0.009827:0.003356:0.009223:0.009827:0.005125:0.003356:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.003356:0.004551:0.009827:0.014182:0.010326:0.003024:0.009223:0.005866:0.003356:0.010311:0.009903:0.005866:0.003024:0.005125:0.003024:0.008376:0.009827:0.004188:0.003356:0.010311:0.009903:0.005125:0.009223:0.003356:0.003024:0.009223:0.003356:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003356:0.010326:0.005125:0.004188
high risk of developing diabetes or patients with estab-:@0.519050:0.143307:0.923802:0.143307:0.923802:0.127525:0.519050:0.127525:0.009223:0.003024:0.010175:0.009223:0.004868:0.004551:0.003024:0.005866:0.007590:0.004883:0.009903:0.004747:0.004868:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.003024:0.009223:0.010175:0.004883:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004883:0.009903:0.004551:0.004868:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004883:0.012564:0.003024:0.005125:0.009223:0.004883:0.009827:0.005866:0.005125:0.010326:0.010311:0.005020
lished diabetes. It is essential to explain to patients that :@0.519050:0.157901:0.928005:0.157901:0.928005:0.142118:0.519050:0.142118:0.003024:0.003024:0.005866:0.009223:0.009827:0.010357:0.004823:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004823:0.003417:0.005125:0.004823:0.003024:0.005866:0.004823:0.009827:0.005866:0.005866:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.004823:0.005125:0.009903:0.004808:0.009827:0.007257:0.010311:0.003024:0.010326:0.003024:0.009223:0.004823:0.005125:0.009903:0.004808:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004823:0.005125:0.009223:0.010326:0.005125:0.004188
NOD associated with statin therapy occurs in patients :@0.519050:0.172494:0.927990:0.172494:0.927990:0.156712:0.519050:0.156712:0.011188:0.013138:0.011249:0.006078:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.006078:0.012564:0.003024:0.005125:0.009223:0.006078:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.006078:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.006078:0.009903:0.009782:0.009782:0.009192:0.004551:0.005866:0.006063:0.003024:0.009223:0.006078:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
with a high baseline risk of becoming diabetic – in other :@0.519050:0.187088:0.928005:0.187088:0.928005:0.171305:0.519050:0.171305:0.012564:0.003024:0.005125:0.009223:0.003916:0.010326:0.003916:0.009223:0.003024:0.010175:0.009223:0.003901:0.010311:0.010326:0.005866:0.009827:0.003024:0.003024:0.009223:0.009827:0.003916:0.004551:0.003024:0.005866:0.007590:0.003916:0.009903:0.004747:0.003901:0.010311:0.009827:0.009782:0.009903:0.014182:0.003024:0.009223:0.010175:0.003901:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.003916:0.007560:0.003916:0.003024:0.009223:0.003916:0.009903:0.005125:0.009223:0.009827:0.004551:0.004188
words, patients with normal glycaemia and no insulin re-:@0.519050:0.201681:0.923802:0.201681:0.923802:0.185899:0.519050:0.185899:0.012564:0.009903:0.004551:0.010357:0.005866:0.004188:0.003447:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003447:0.012564:0.003024:0.005125:0.009223:0.003447:0.009223:0.009903:0.004551:0.014182:0.010326:0.003024:0.003447:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.010326:0.003447:0.010326:0.009223:0.010357:0.003447:0.009223:0.009903:0.003447:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.003447:0.004551:0.009827:0.005020
sistance will not suddenly become diabetic if they take :@0.519050:0.216275:0.928005:0.216275:0.928005:0.200492:0.519050:0.200492:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004415:0.012564:0.003024:0.003024:0.003024:0.004430:0.009223:0.009903:0.005125:0.004415:0.005866:0.009192:0.010357:0.010357:0.009827:0.009223:0.003024:0.008104:0.004430:0.010311:0.009827:0.009782:0.009903:0.014182:0.009827:0.004415:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.004430:0.003024:0.004747:0.004415:0.005125:0.009223:0.009827:0.008104:0.004415:0.005125:0.010326:0.007590:0.009827:0.004188
a statin. Also, statins do not have a measurable nega-:@0.519050:0.230868:0.923817:0.230868:0.923817:0.215086:0.519050:0.215086:0.010326:0.005367:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.005352:0.011188:0.003024:0.005866:0.009903:0.004188:0.005352:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.005367:0.010357:0.009903:0.005352:0.009223:0.009903:0.005125:0.005352:0.009223:0.010326:0.008376:0.009827:0.005367:0.010326:0.005367:0.014182:0.009827:0.010326:0.005866:0.009192:0.004551:0.010326:0.010311:0.003024:0.009827:0.005367:0.009223:0.009827:0.010175:0.010326:0.005020
tive effect  on glycaemic control  in diabetic patients. :@0.519050:0.245462:0.927990:0.245462:0.927990:0.229679:0.519050:0.229679:0.005125:0.003024:0.008376:0.009827:0.006925:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.002721:0.009903:0.009223:0.006925:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.006925:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.004188:0.002721:0.003024:0.009223:0.006925:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.006925:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004188
starting a statin in a patient with diabetes will, therefore, :@0.519050:0.260055:0.928005:0.260055:0.928005:0.244272:0.519050:0.244272:0.007529:0.005125:0.010326:0.004551:0.005125:0.003024:0.009223:0.010175:0.003659:0.010326:0.003659:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.003659:0.003024:0.009223:0.003659:0.010326:0.003659:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.003659:0.012564:0.003024:0.005125:0.009223:0.003659:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.003659:0.012564:0.003024:0.003024:0.003024:0.004188:0.003674:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.004188:0.004188
reduce cardiovascular risk without significantly impact:@0.519050:0.274649:0.918782:0.274649:0.918782:0.258866:0.519050:0.258866:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004914:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004929:0.004551:0.003024:0.005866:0.007590:0.004929:0.012564:0.003024:0.005125:0.009223:0.009903:0.009192:0.005125:0.004914:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003024:0.008104:0.004929:0.003024:0.014182:0.010311:0.010326:0.009782:0.005125
-:@0.918782:0.274649:0.923802:0.274649:0.923802:0.258866:0.918782:0.258866:0.005020
ing glycaemic control. :@0.519050:0.289242:0.687960:0.289242:0.687960:0.273459:0.519050:0.273459:0.003024:0.009223:0.010175:0.004188:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.004188:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.004188:0.004188
Haemorrhagic stroke :@0.519047:0.320921:0.695100:0.320921:0.695100:0.302590:0.519047:0.302590:0.011423:0.011087:0.010751:0.015791:0.010751:0.005376:0.005376:0.010079:0.011087:0.011087:0.004032:0.010751:0.004704:0.007392:0.005040:0.005376:0.010751:0.009743:0.010751:0.004704
In  observational studies, low cholesterol  is associated :@0.519047:0.337688:0.928002:0.337688:0.928002:0.321905:0.519047:0.321905:0.003417:0.009223:0.004188:0.003145:0.009903:0.010311:0.005866:0.009827:0.004551:0.008376:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.007348:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.007348:0.003024:0.009903:0.012564:0.007348:0.009782:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.009827:0.004551:0.009903:0.003024:0.004188:0.003145:0.003024:0.005866:0.007348:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.004188
with a slightly increased risk of intracranial bleed-:@0.519047:0.352281:0.923784:0.352281:0.923784:0.336498:0.519047:0.336498:0.012564:0.003024:0.005125:0.009223:0.011082:0.010326:0.011082:0.005866:0.003024:0.003024:0.010175:0.009223:0.005125:0.003024:0.008104:0.011082:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.011082:0.004551:0.003024:0.005866:0.007590:0.011082:0.009903:0.004747:0.011082:0.003024:0.009223:0.005125:0.004551:0.010326:0.009782:0.004551:0.010326:0.009223:0.003024:0.010326:0.003024:0.011082:0.010311:0.003024:0.009827:0.009827:0.010357:0.005020
ing. However, some confusion may be present as low :@0.519047:0.366874:0.927987:0.366874:0.927987:0.351092:0.519047:0.351092:0.003024:0.009223:0.010175:0.004188:0.006093:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.006093:0.005866:0.009903:0.014182:0.009827:0.006093:0.009782:0.009903:0.009223:0.004747:0.009192:0.005866:0.003024:0.009903:0.009223:0.006093:0.014182:0.010326:0.008104:0.006108:0.010311:0.009827:0.006093:0.010311:0.004551:0.009827:0.005866:0.009827:0.009223:0.005125:0.006093:0.010326:0.005866:0.006108:0.003024:0.009903:0.012564:0.004188
cholesterol  is often  a  marker  of  poor  general  health. :@0.519047:0.381468:0.928002:0.381468:0.928002:0.365685:0.519047:0.365685:0.009782:0.009223:0.009903:0.003024:0.009827:0.005866:0.005125:0.009827:0.004551:0.009903:0.003024:0.004188:0.003115:0.003024:0.005866:0.007318:0.009903:0.004747:0.005125:0.009827:0.009223:0.004188:0.003115:0.010326:0.004188:0.003115:0.014182:0.010326:0.004551:0.007590:0.009827:0.004551:0.004188:0.003115:0.009903:0.004747:0.004188:0.003115:0.010311:0.009903:0.009903:0.004551:0.004188:0.003115:0.010175:0.009827:0.009223:0.009827:0.004551:0.010326:0.003024:0.004188:0.003115:0.009223:0.009827:0.010326:0.003024:0.005125:0.009223:0.004188:0.004188
In the  spARCL  study, patients with a stroke  one  to  six :@0.519047:0.396061:0.928002:0.396061:0.928002:0.380279:0.519047:0.380279:0.003417:0.009223:0.006698:0.005125:0.009223:0.009827:0.004188:0.002510:0.007529:0.008950:0.011188:0.009177:0.012292:0.006985:0.004188:0.002495:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.006698:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006698:0.012564:0.003024:0.005125:0.009223:0.006698:0.010326:0.006698:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.002495:0.009903:0.009223:0.009827:0.004188:0.002495:0.005125:0.009903:0.004188:0.002495:0.005866:0.003024:0.007257:0.004188
months  before enrolment  were  randomised either  to :@0.519047:0.410655:0.927987:0.410655:0.927987:0.394872:0.519047:0.394872:0.014182:0.009903:0.009223:0.005125:0.009223:0.005866:0.004188:0.003508:0.010311:0.009827:0.004747:0.009903:0.004551:0.009812:0.007711:0.009827:0.009223:0.004551:0.009903:0.003024:0.014182:0.009827:0.009223:0.005125:0.004188:0.003508:0.012564:0.009827:0.004551:0.009827:0.004188:0.003508:0.004551:0.010326:0.009223:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.007711:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.004188:0.003508:0.005125:0.009903:0.004188
atorvastatin 80 mg/day or placebo. Atorvastatin mark-:@0.519047:0.425248:0.923784:0.425248:0.923784:0.409466:0.519047:0.409466:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004838:0.008376:0.008376:0.004838:0.014182:0.010175:0.006607:0.010357:0.010326:0.008104:0.004838:0.009903:0.004551:0.004823:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.004823:0.011188:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004823:0.014182:0.010326:0.004551:0.007590:0.005020
edly reduced the overall stroke risk, and this was due :@0.519047:0.439842:0.928017:0.439842:0.928017:0.424059:0.519047:0.424059:0.009827:0.010357:0.003024:0.008104:0.006335:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.006335:0.005125:0.009223:0.009827:0.006335:0.009903:0.008376:0.009827:0.004551:0.010326:0.003024:0.003024:0.006335:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.006335:0.004551:0.003024:0.005866:0.007590:0.004188:0.006335:0.010326:0.009223:0.010357:0.006335:0.005125:0.009223:0.003024:0.005866:0.006335:0.012564:0.010326:0.005866:0.006335:0.010357:0.009192:0.009827:0.004188
to  a decrease in ischaemic strokes.  The  incidence of :@0.519047:0.454435:0.927987:0.454435:0.927987:0.438652:0.519047:0.438652:0.005125:0.009903:0.004188:0.002631:0.010326:0.006834:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.006834:0.003024:0.009223:0.006834:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.006834:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.005866:0.004188:0.004188:0.002631:0.006441:0.009223:0.009827:0.004188:0.002631:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.006834:0.009903:0.004747:0.004188
haemorrhagic  stroke  was 2.3% in patients on atorvas-:@0.519047:0.469029:0.923799:0.469029:0.923799:0.453246:0.519047:0.453246:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009782:0.004188:0.002328:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.002328:0.012564:0.010326:0.005866:0.006531:0.008376:0.004188:0.008376:0.011717:0.006531:0.003024:0.009223:0.006531:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006531:0.009903:0.009223:0.006531:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005020
tatin, compared with 1.4% in placebo-treated controls, :@0.519047:0.483622:0.928017:0.483622:0.928017:0.467839:0.519047:0.467839:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.004747:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004747:0.012564:0.003024:0.005125:0.009223:0.004747:0.008376:0.004188:0.008376:0.011717:0.004747:0.003024:0.009223:0.004747:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.005020:0.005125:0.004551:0.009827:0.010326:0.005125:0.009827:0.010357:0.004747:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.005866:0.004188:0.004188
but most haemorrhagic  strokes occurred  in the small :@0.519047:0.498215:0.928002:0.498215:0.928002:0.482433:0.519047:0.482433:0.010311:0.009192:0.005125:0.007212:0.014182:0.009903:0.005866:0.005125:0.007212:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009782:0.004188:0.003009:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.005866:0.007212:0.009903:0.009782:0.009782:0.009192:0.004551:0.004551:0.009827:0.010357:0.004188:0.003009:0.003024:0.009223:0.007212:0.005125:0.009223:0.009827:0.007212:0.005866:0.014182:0.010326:0.003024:0.003024:0.004188
number of patients randomised to the trial with a base-:@0.519047:0.512809:0.923784:0.512809:0.923784:0.497026:0.519047:0.497026:0.009223:0.009192:0.014182:0.010311:0.009827:0.004551:0.004385:0.009903:0.004747:0.004385:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004385:0.004551:0.010326:0.009223:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.004385:0.005125:0.009903:0.004385:0.005125:0.009223:0.009827:0.004385:0.005125:0.004551:0.003024:0.010326:0.003024:0.004400:0.012564:0.003024:0.005125:0.009223:0.004385:0.010326:0.004400:0.010311:0.010326:0.005866:0.009827:0.005020
line haemorrhagic  stroke.  subsequent cardiovascular :@0.519047:0.527402:0.928002:0.527402:0.928002:0.511620:0.519047:0.511620:0.003024:0.003024:0.009223:0.009827:0.007937:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009782:0.004188:0.003734:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.004188:0.003750:0.007529:0.009192:0.010311:0.005866:0.009827:0.010311:0.009192:0.009827:0.009223:0.005125:0.007937:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
outcome  studies with statins and other  lipid-lowering :@0.519047:0.541996:0.927987:0.541996:0.927987:0.526213:0.519047:0.526213:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.004188:0.003719:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.007922:0.012564:0.003024:0.005125:0.009223:0.007922:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.007922:0.010326:0.009223:0.010357:0.007922:0.009903:0.005125:0.009223:0.009827:0.004551:0.004188:0.003719:0.003024:0.003024:0.010311:0.003024:0.010357:0.005020:0.003024:0.009903:0.012564:0.009827:0.004551:0.003024:0.009223:0.010175:0.004188
medications have not  found  a consistent  increase  in :@0.519047:0.556589:0.928002:0.556589:0.928002:0.540807:0.519047:0.540807:0.014182:0.009827:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.007257:0.009223:0.010326:0.008376:0.009827:0.007257:0.009223:0.009903:0.005125:0.004188:0.003054:0.004747:0.009903:0.009192:0.009223:0.010357:0.004188:0.003054:0.010326:0.007257:0.009782:0.009903:0.009223:0.005866:0.003024:0.005866:0.005125:0.009827:0.009223:0.005125:0.004188:0.003054:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004188:0.003054:0.003024:0.009223:0.004188
haemorrhagic  stroke.  statins should  thus  not  be  with-:@0.519047:0.571183:0.923799:0.571183:0.923799:0.555400:0.519047:0.555400:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009782:0.004188:0.002963:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.004188:0.002963:0.007529:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.007166:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004188:0.002963:0.005125:0.009223:0.009192:0.005866:0.004188:0.002963:0.009223:0.009903:0.005125:0.004188:0.002963:0.010311:0.009827:0.004188:0.002963:0.012564:0.003024:0.005125:0.009223:0.005020
held in patients with an ischaemic stroke for fear of con-:@0.519047:0.585776:0.923799:0.585776:0.923799:0.569994:0.519047:0.569994:0.009223:0.009827:0.003024:0.010357:0.003659:0.003024:0.009223:0.003674:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003674:0.012564:0.003024:0.005125:0.009223:0.003659:0.010326:0.009223:0.003659:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.003674:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.003659:0.004747:0.009903:0.004551:0.003659:0.004747:0.009827:0.010326:0.004551:0.003659:0.009903:0.004747:0.003659:0.009782:0.009903:0.009223:0.005020
verting this to a haemorrhagic stroke. In patients with a :@0.519047:0.600370:0.927987:0.600370:0.927987:0.584587:0.519047:0.584587:0.008376:0.009827:0.004551:0.005125:0.003024:0.009223:0.010175:0.004657:0.005125:0.009223:0.003024:0.005866:0.004672:0.005125:0.009903:0.004657:0.010326:0.004672:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009767:0.004672:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.004657:0.003417:0.009223:0.004672:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004672:0.012564:0.003024:0.005125:0.009223:0.004672:0.010326:0.004188
strong indication for a statin (e.g. established coronary :@0.519047:0.614963:0.928002:0.614963:0.928002:0.599180:0.519047:0.599180:0.005866:0.005125:0.004551:0.009903:0.009223:0.010175:0.005080:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005095:0.004747:0.009903:0.004551:0.005080:0.010326:0.005095:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005095:0.005579:0.009827:0.004188:0.010175:0.004188:0.005080:0.009827:0.005866:0.005125:0.010326:0.010311:0.003024:0.003024:0.005866:0.009223:0.009827:0.010357:0.005095:0.009782:0.009903:0.004551:0.009903:0.009223:0.010326:0.004551:0.008104:0.004188
artery disease), statins should not be discontinued, even :@0.519047:0.629556:0.927987:0.629556:0.927987:0.613774:0.519047:0.613774:0.010326:0.004551:0.005125:0.009827:0.004551:0.008104:0.003508:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005579:0.004188:0.003508:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.003508:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003508:0.009223:0.009903:0.005125:0.003508:0.010311:0.009827:0.003508:0.010357:0.003024:0.005866:0.009782:0.009903:0.009223:0.005125:0.003024:0.009223:0.009192:0.009827:0.010357:0.004188:0.003508:0.009827:0.008376:0.009827:0.009223:0.004188
if patients experience a haemorrhagic stroke.:@0.519047:0.644150:0.852513:0.644150:0.852513:0.628367:0.519047:0.628367:0.003024:0.004747:0.004188:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.009827:0.007257:0.010311:0.009827:0.004551:0.003024:0.009827:0.009223:0.009782:0.009827:0.004188:0.010326:0.004188:0.009223:0.010326:0.009827:0.014182:0.009903:0.004551:0.004551:0.009223:0.010326:0.010175:0.003024:0.009782:0.004188:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188
Hepatic dysfunction:@0.519047:0.675840:0.681661:0.675840:0.681661:0.657508:0.519047:0.657508:0.011423:0.010751:0.011087:0.011087:0.005040:0.004032:0.010751:0.004704:0.011087:0.009743:0.007392:0.004704:0.010079:0.010079:0.010751:0.005040:0.004032:0.010751:0.010079
statins very infrequently cause severe liver disease, and :@0.519047:0.692606:0.928002:0.692606:0.928002:0.676824:0.519047:0.676824:0.007529:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004324:0.008376:0.009827:0.004551:0.008104:0.004309:0.003024:0.009223:0.004747:0.004551:0.009827:0.010311:0.009192:0.009827:0.009223:0.005125:0.003024:0.008104:0.004324:0.009782:0.010326:0.009192:0.005866:0.009827:0.004324:0.005866:0.009827:0.008376:0.009827:0.004551:0.009827:0.004324:0.003024:0.003024:0.008376:0.009827:0.004551:0.004324:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.004324:0.010326:0.009223:0.010357:0.004188
routine monitoring of liver function tests is not required :@0.519047:0.707200:0.927972:0.707200:0.927972:0.691417:0.519047:0.691417:0.004551:0.009903:0.009192:0.005125:0.003024:0.009223:0.009827:0.005655:0.014182:0.009903:0.009223:0.003024:0.005125:0.009903:0.004551:0.003024:0.009223:0.010175:0.005655:0.009903:0.004747:0.005670:0.003024:0.003024:0.008376:0.009827:0.004551:0.005670:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.005655:0.005125:0.009827:0.005866:0.005125:0.005866:0.005670:0.003024:0.005866:0.005670:0.009223:0.009903:0.005125:0.005655:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.009827:0.010357:0.004188
in patients on statins. In patients with elevated liver en-:@0.519047:0.721793:0.923799:0.721793:0.923799:0.706011:0.519047:0.706011:0.003024:0.009223:0.004989:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004974:0.009903:0.009223:0.004974:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004188:0.004974:0.003417:0.009223:0.004989:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004974:0.012564:0.003024:0.005125:0.009223:0.004989:0.009827:0.003024:0.009827:0.008376:0.010326:0.005125:0.009827:0.010357:0.004989:0.003024:0.003024:0.008376:0.009827:0.004551:0.004989:0.009827:0.009223:0.005020
zymes on statins, it is important not to ascribe the abnor-:@0.519047:0.736387:0.923814:0.736387:0.923814:0.720604:0.519047:0.720604:0.006426:0.008104:0.014182:0.009827:0.005866:0.003719:0.009903:0.009223:0.003719:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004188:0.003719:0.003024:0.005125:0.003719:0.003024:0.005866:0.003734:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.003719:0.009223:0.009903:0.005125:0.003719:0.005125:0.009903:0.003719:0.010326:0.005866:0.009782:0.004551:0.003024:0.010311:0.009827:0.003719:0.005125:0.009223:0.009827:0.003719:0.010326:0.010311:0.009223:0.009903:0.004551:0.005020
mality to statin therapy, but to consider other possible :@0.519047:0.750980:0.927987:0.750980:0.927987:0.735197:0.519047:0.735197:0.014182:0.010326:0.003024:0.003024:0.005125:0.008104:0.005836:0.005125:0.009903:0.005821:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005836:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.005821:0.010311:0.009192:0.005125:0.005836:0.005125:0.009903:0.005836:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.005836:0.009903:0.005125:0.009223:0.009827:0.004551:0.005821:0.010311:0.009903:0.005866:0.005866:0.003024:0.010311:0.003024:0.009827:0.004188
explanations, such as alcohol, non-alcoholic fatty liver :@0.519047:0.765574:0.928002:0.765574:0.928002:0.749791:0.519047:0.749791:0.009827:0.007257:0.010311:0.003024:0.010326:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.005655:0.005866:0.009192:0.009782:0.009223:0.005655:0.010326:0.005866:0.005655:0.010326:0.003024:0.009782:0.009903:0.009223:0.009903:0.003024:0.004188:0.005655:0.009223:0.009903:0.009223:0.005020:0.010326:0.003024:0.009782:0.009903:0.009223:0.009903:0.003024:0.003024:0.009782:0.005655:0.004747:0.010326:0.005125:0.005125:0.008104:0.005655:0.003024:0.003024:0.008376:0.009827:0.004551:0.004188
disease, iron overload or viral hepatitis.:@0.519047:0.780167:0.802030:0.780167:0.802030:0.764384:0.519047:0.764384:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.004188:0.003024:0.004551:0.009903:0.009223:0.004188:0.009903:0.008376:0.009827:0.004551:0.003024:0.009903:0.010326:0.010357:0.004188:0.009903:0.004551:0.004188:0.008376:0.003024:0.004551:0.010326:0.003024:0.004188:0.009223:0.009827:0.010311:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.004188
risks in pregnancy and breastfeeding :@0.519047:0.811839:0.830499:0.811839:0.830499:0.793508:0.519047:0.793508:0.009743:0.004032:0.007392:0.009743:0.007392:0.004704:0.004032:0.010079:0.004704:0.011087:0.005376:0.010751:0.011087:0.010079:0.011087:0.010079:0.010751:0.009743:0.004704:0.011087:0.010079:0.011087:0.004704:0.011087:0.005376:0.010751:0.011087:0.007392:0.005040:0.004704:0.010751:0.010751:0.011087:0.004032:0.010079:0.011087:0.004704
statins are rated as category X in pregnancy and must :@0.519047:0.828606:0.928063:0.828606:0.928063:0.812823:0.519047:0.812823:0.007378:0.004974:0.010175:0.004974:0.002873:0.009071:0.005715:0.005443:0.010175:0.004400:0.009676:0.005443:0.004400:0.010175:0.004974:0.009676:0.010205:0.005443:0.010175:0.005715:0.005443:0.009631:0.010175:0.004974:0.009676:0.010024:0.009752:0.004400:0.007953:0.005443:0.009056:0.005443:0.002873:0.009071:0.005443:0.010160:0.004400:0.009676:0.010024:0.009071:0.010175:0.009071:0.009631:0.007953:0.005443:0.010175:0.009071:0.010205:0.005443:0.014030:0.009041:0.005715:0.005125:0.004188
be discontinued before conception, whenever possible. :@0.519047:0.843199:0.927987:0.843199:0.927987:0.827416:0.519047:0.827416:0.010160:0.009676:0.004324:0.010205:0.002873:0.005715:0.009631:0.009752:0.009071:0.004974:0.002873:0.009071:0.009041:0.009676:0.010205:0.004324:0.010160:0.009676:0.004596:0.009752:0.004400:0.009676:0.004324:0.009631:0.009752:0.009071:0.009631:0.009676:0.010160:0.004974:0.002873:0.009752:0.009071:0.004037:0.004324:0.012413:0.009071:0.009676:0.009071:0.009676:0.008225:0.009676:0.004400:0.004324:0.010160:0.009752:0.005715:0.005715:0.002873:0.010160:0.002873:0.009676:0.004188:0.004188
However, should a patient inadvertently conceive while :@0.519047:0.857793:0.928002:0.857793:0.928002:0.842010:0.519047:0.842010:0.010175:0.009752:0.012413:0.009676:0.008225:0.009676:0.004400:0.004037:0.004657:0.005715:0.009071:0.009752:0.009041:0.002873:0.010205:0.004657:0.010175:0.004657:0.010160:0.010175:0.004974:0.002873:0.009676:0.009071:0.004974:0.004657:0.002873:0.009071:0.010175:0.010205:0.008225:0.009676:0.004400:0.004974:0.009676:0.009071:0.004974:0.002873:0.007953:0.004657:0.009631:0.009752:0.009071:0.009631:0.009676:0.002873:0.008225:0.009676:0.004657:0.012413:0.009071:0.002873:0.002873:0.009827:0.004188
taking a statin, the risk to the foetus is very small, and :@0.519047:0.872386:0.927957:0.872386:0.927957:0.856603:0.519047:0.856603:0.004974:0.010175:0.007439:0.002873:0.009071:0.010024:0.006698:0.010175:0.006698:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.004037:0.006698:0.004974:0.009071:0.009676:0.006698:0.004400:0.002873:0.005715:0.007439:0.006698:0.004974:0.009752:0.006698:0.004974:0.009071:0.009676:0.006698:0.004596:0.009752:0.009676:0.004974:0.009041:0.005715:0.006698:0.002873:0.005715:0.006698:0.008225:0.009676:0.004400:0.007953:0.006698:0.005715:0.014030:0.010175:0.002873:0.002873:0.004037:0.006698:0.010175:0.009071:0.010357:0.004188
there is no need to terminate the pregnancy. Data on :@0.519047:0.886979:0.928032:0.886979:0.928032:0.871197:0.519047:0.871197:0.004974:0.009071:0.009676:0.004400:0.009676:0.005896:0.002873:0.005715:0.005896:0.009071:0.009752:0.005896:0.009071:0.009676:0.009676:0.010205:0.005896:0.004974:0.009752:0.005896:0.004974:0.009676:0.004400:0.014030:0.002873:0.009071:0.010175:0.004974:0.009676:0.005896:0.004974:0.009071:0.009676:0.005896:0.010160:0.004400:0.009676:0.010024:0.009071:0.010175:0.009071:0.009631:0.007953:0.004037:0.005896:0.011097:0.010175:0.004974:0.010175:0.005896:0.009752:0.009223:0.004188
the safety of statins in breastfeeding are minimal. Gener-:@0.519047:0.901573:0.923769:0.901573:0.923769:0.885790:0.519047:0.885790:0.004974:0.009071:0.009676:0.003976:0.005715:0.010175:0.004596:0.009676:0.004974:0.007953:0.003976:0.009752:0.004596:0.003976:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.005715:0.003976:0.002873:0.009071:0.003976:0.010160:0.004400:0.009676:0.010175:0.005715:0.004974:0.004596:0.009676:0.009676:0.010205:0.002873:0.009071:0.010024:0.003976:0.010175:0.004400:0.009676:0.003976:0.014030:0.002873:0.009071:0.002873:0.014030:0.010175:0.002873:0.004037:0.003976:0.013033:0.009676:0.009071:0.009676:0.004400:0.005020
ally, the use of statins by breastfeeding mothers is discour-:@0.519047:0.916166:0.923844:0.916166:0.923844:0.900384:0.519047:0.900384:0.010175:0.002873:0.002873:0.007953:0.004037:0.003190:0.004974:0.009071:0.009676:0.003190:0.009041:0.005715:0.009676:0.003190:0.009752:0.004596:0.003190:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.005715:0.003190:0.010160:0.007953:0.003190:0.010160:0.004400:0.009676:0.010175:0.005715:0.004974:0.004596:0.009676:0.009676:0.010205:0.002873:0.009071:0.010024:0.003190:0.014030:0.009752:0.004974:0.009071:0.009676:0.004400:0.005715:0.003190:0.002873:0.005715:0.003190:0.010205:0.002873:0.005715:0.009631:0.009752:0.009041:0.004400:0.005020
aged, although more recent literature has questioned :@0.519047:0.930760:0.928032:0.930760:0.928032:0.914977:0.519047:0.914977:0.010175:0.010024:0.009676:0.010205:0.004037:0.006849:0.010175:0.002873:0.004974:0.009071:0.009752:0.009041:0.010024:0.009071:0.006849:0.014030:0.009752:0.004400:0.009676:0.006849:0.004400:0.009676:0.009631:0.009676:0.009071:0.004974:0.006849:0.002873:0.002873:0.004974:0.009676:0.004400:0.010175:0.004974:0.009041:0.004400:0.009676:0.006849:0.009071:0.010175:0.005715:0.006849:0.010160:0.009041:0.009676:0.005715:0.004974:0.002873:0.009752:0.009071:0.009676:0.010357:0.004188
this, especially for hydrophilic statins like rosuvastatin.:@0.519047:0.945353:0.894786:0.945353:0.894786:0.929571:0.519047:0.929571:0.004974:0.009071:0.002873:0.005715:0.004037:0.004037:0.009676:0.005715:0.010160:0.009676:0.009631:0.002873:0.010175:0.002873:0.002873:0.007953:0.004037:0.004596:0.009752:0.004400:0.004037:0.009071:0.007953:0.010205:0.004400:0.009752:0.010160:0.009071:0.002873:0.002873:0.002873:0.009631:0.004037:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.005715:0.004037:0.002873:0.002873:0.007439:0.009676:0.004037:0.004400:0.009752:0.005715:0.009041:0.008225:0.010175:0.005715:0.004974:0.010175:0.004974:0.002873:0.009071:0.004188
13:@0.894636:0.940064:0.904265:0.940064:0.904265:0.930910:0.894636:0.930910:0.004770:0.004858